GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Marksans Pharma Ltd (NSE:MARKSANS) » Definitions » Cyclically Adjusted Revenue per Share

Marksans Pharma (NSE:MARKSANS) Cyclically Adjusted Revenue per Share : ₹36.00 (As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Marksans Pharma Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Marksans Pharma's adjusted revenue per share for the three months ended in Dec. 2023 was ₹12.957. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹36.00 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Marksans Pharma's average Cyclically Adjusted Revenue Growth Rate was 11.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-26), Marksans Pharma's current stock price is ₹168.45. Marksans Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was ₹36.00. Marksans Pharma's Cyclically Adjusted PS Ratio of today is 4.68.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Marksans Pharma was 4.84. The lowest was 1.44. And the median was 2.14.


Marksans Pharma Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Marksans Pharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marksans Pharma Cyclically Adjusted Revenue per Share Chart

Marksans Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 28.90 33.10

Marksans Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.30 33.10 34.35 35.10 36.00

Competitive Comparison of Marksans Pharma's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Marksans Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marksans Pharma's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Marksans Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Marksans Pharma's Cyclically Adjusted PS Ratio falls into.



Marksans Pharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Marksans Pharma's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=12.957/152.9243*152.9243
=12.957

Current CPI (Dec. 2023) = 152.9243.

Marksans Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 4.126 91.425 6.901
201406 5.245 94.103 8.524
201409 5.471 96.780 8.645
201412 5.541 96.780 8.755
201503 3.539 97.163 5.570
201506 5.142 99.841 7.876
201509 6.229 101.753 9.362
201512 5.334 102.901 7.927
201603 5.128 102.518 7.649
201606 4.636 105.961 6.691
201609 5.307 105.961 7.659
201612 5.188 105.196 7.542
201703 4.246 105.196 6.172
201706 5.060 107.109 7.224
201709 6.683 109.021 9.374
201712 5.131 109.404 7.172
201803 5.789 109.786 8.064
201806 5.484 111.317 7.534
201809 6.277 115.142 8.337
201812 5.929 115.142 7.875
201903 6.489 118.202 8.395
201906 5.668 120.880 7.171
201909 6.220 123.175 7.722
201912 6.909 126.235 8.370
202003 8.719 124.705 10.692
202006 8.050 127.000 9.693
202009 8.502 130.118 9.992
202012 8.634 130.889 10.088
202103 8.235 131.771 9.557
202106 8.520 134.084 9.717
202109 8.813 135.847 9.921
202112 8.859 138.161 9.806
202203 9.971 138.822 10.984
202206 10.605 142.347 11.393
202209 11.230 144.661 11.871
202212 11.805 145.763 12.385
202303 10.907 146.865 11.357
202306 11.070 150.280 11.265
202309 11.704 151.492 11.815
202312 12.957 152.924 12.957

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Marksans Pharma  (NSE:MARKSANS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Marksans Pharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=168.45/36
=4.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Marksans Pharma was 4.84. The lowest was 1.44. And the median was 2.14.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Marksans Pharma Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Marksans Pharma's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Marksans Pharma (NSE:MARKSANS) Business Description

Industry
Traded in Other Exchanges
Address
Veera Desai Extension Road, 11th Floor, Grandeur, Opposite Gundecha Symphony, Oshiwara, Andheri (West), Mumbai, MH, IND, 400053
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal and oncologic drugs as well as antibiotics and antiallergic medications. It has a market presence with the majority of the revenue generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, India, and the Rest of the World.

Marksans Pharma (NSE:MARKSANS) Headlines

No Headlines